Enidap may be available in the countries listed below.
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Enidap in the following countries:
International Drug Name Search
Esomeprazole Magnesium may be available in the countries listed below.
Esomeprazole Magnesium (BAN, USAN) is known as Esomeprazole in the US.
International Drug Name Search
Glossary
| BAN | British Approved Name |
| USAN | United States Adopted Name |
Supremon may be available in the countries listed below.
Buserelin acetate (a derivative of Buserelin) is reported as an ingredient of Supremon in the following countries:
International Drug Name Search
Levam may be available in the countries listed below.
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Levam in the following countries:
International Drug Name Search
Hepanavit may be available in the countries listed below.
Silibinin is reported as an ingredient of Hepanavit in the following countries:
International Drug Name Search
Mg Inresa may be available in the countries listed below.
Magnesium Sulfate heptahydrate (a derivative of Magnesium Sulfate) is reported as an ingredient of Mg Inresa in the following countries:
International Drug Name Search
Alve may be available in the countries listed below.
Tiemonium Methylsulfate is reported as an ingredient of Alve in the following countries:
International Drug Name Search
Lisiken may be available in the countries listed below.
Clindamycin hydrochloride (a derivative of Clindamycin) is reported as an ingredient of Lisiken in the following countries:
International Drug Name Search
Norinyl T28 may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Norinyl T28 in the following countries:
Norethisterone is reported as an ingredient of Norinyl T28 in the following countries:
International Drug Name Search
Calcidia may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcidia in the following countries:
International Drug Name Search
Rhinox may be available in the countries listed below.
Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Rhinox in the following countries:
International Drug Name Search
Piroxicam Biogaran may be available in the countries listed below.
Piroxicam is reported as an ingredient of Piroxicam Biogaran in the following countries:
International Drug Name Search
Pyopen may be available in the countries listed below.
Carbenicillin disodium salt (a derivative of Carbenicillin) is reported as an ingredient of Pyopen in the following countries:
International Drug Name Search
Rec.INN
0032909-92-5
C9-H10-N4-O3-S2
286
Antibacterial: Sulfonamid
Benzenesulfonamide, 4-amino-N-(4-methoxy-1,2,5-thiadiazol-3-yl)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Rx Only
Benzoyl Peroxide Cleanser 3%, 6%, and 9% are topical, gel-based, benzoyl peroxide containing preparations for use in the treatment of acne vulgaris. Benzoyl peroxide is an oxidizing agent that possesses antibacterial properties and is classified as a keratolytic.
Benzoyl peroxide (C14H10O4) is represented by the following chemical structure:
Benzoyl Peroxide Cleanser 3%, 6% and 9% contain hydrous benzoyl peroxide 3%, 6% and 9% as the active ingredient in a vehicle consisting of: alpha olefin sulfonate, cetostearyl alcohol, glycerin, glyceryl monostearate SE, methylparaben, phosphoric acid, propylene glycol, sodium PCA, white petrolatum and purified water.
The mechanism of action of benzoyl peroxide is not totally understood but its antibacterial activity against Propionibacterium acnes is thought to be a major mode of action. In addition, patients treated with benzoyl peroxide show a reduction in lipids and free fatty acids, and mild desquamation (drying and peeling activity) with simultaneous reduction in comedones and acne lesions. Little is known about the percutaneous penetration, metabolism, and excretion of benzoyl peroxide, although it has been shown that benzoyl peroxide absorbed by the skin is metabolized to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by benzoyl peroxide in humans.
Benzoyl Peroxide Cleanser 3%, 6%, and 9% is indicated for the topical treatment of acne vulgaris.
These preparations are contraindicated in patients with a history of hypersensitivity to any of their components.
When using this product, avoid unnecessary sun exposure and use a sunscreen.
For external use only. If severe irritation develops, discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes.
Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Contact with any colored material (including hair and fabric) may result in bleaching or discoloration. If excessive irritation develops, discontinue use and consult your physician.
Data from several studies employing a strain of mice that are highly susceptible to developing cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of these findings to humans is unknown. Benzoyl peroxide has not been found to be mutagenic (Ames Test) and there are no published data indicating it impairs fertility.
Pregnancy Category C: Animal reproduction studies have not been conducted with benzoyl peroxide. It is not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can effect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed. There are no available data on the effect of benzoyl peroxide on the later growth, development and functional maturation of the unborn child.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzoyl peroxide is administered to a nursing woman.
Safety and effectiveness in children have not been established.
Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.
If excessive scaling, erythema or edema occurs, the use of these preparations should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.
Benzoyl Peroxide Cleansers: Wash affected areas once or twice daily, or as directed by your dermatologist. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 to 20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.
Benzoyl Peroxide Cleanser 3%
6 oz. (170 g) tube - NDC 68462-411-38
12 oz. (340 g) bottle - NDC 68462-411-34
Benzoyl Peroxide Cleanser 6%
6 oz. (170 g) tube - NDC 68462-412-38
12 oz. (340 g) bottle - NDC 68462-412-34
Benzoyl Peroxide Cleanser 9%
6 oz. (170 g) tube - NDC 68462-413-38
12 oz. (340 g) bottle - NDC 68462-413-34
Store at 15° to 25°C (59° to 77°F). [see USP Controlled Room Temperature].
Manufactured by:
Glenmark Generics Ltd.
Colvale-Bardez, Goa 403 513, India
Manufactured for:
Glenmark Generics Inc., USA
Mahwah, NJ 07430
Questions? 1 (888)721-7115
www.glenmarkgenerics.com
February 2009
| BENZOYL PEROXIDE benzoyl peroxide solution | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other | 03/20/2009 | ||
| BENZOYL PEROXIDE benzoyl peroxide solution | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other | 03/20/2009 | ||
| BENZOYL PEROXIDE benzoyl peroxide solution | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other | 03/20/2009 | ||
| Labeler - Glenmark Generics Inc., USA (835917282) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Glenmark Generics Limited | 677318665 | ANALYSIS, MANUFACTURE | |
